Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves
Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, Mounjaro and Zepbound, after the FDA declares the tirzepatide shortage resolved.
Eli Lilly (NYSE:LLY) has expanded its ongoing collaboration with Swiss biotech KeyBioscience in a bid to obtain global rights ...
The justices are considering an effort challenging longstanding case law blocking the state’s ability to probe inflated drug ...
Eli Lilly’s shares have surged 750 per cent over five years. Novo Nordisk’s are up about 360 per cent in the same period.
Drug giant Eli Lilly announced Thomas Fuchs as its first chief AI officer. Previously, Fuchs was director of the Hasso ...
The Michigan attorney general’s department, which wants to probe Eli Lilly & Co.’s insulin pricing practices, urged the state ...
Eli Lilly and Company (NYSE:LLY – Get Free Report) shares rose 2.3% on Tuesday . The company traded as high as $920.28 and ...
Insitro has teamed up with Eli Lilly to help power programs into the clinic, tapping the Big Pharma for an option on ...
Eli Lilly (LLY) has reportedly sent out cease-and-desist letters to compounding pharmacies and clinics that were providing copycat versions of its drugs Zepbound and Mounjaro.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback